Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
NASDAQ:SHPH
Holding SHPH?
Track your performance easily
SHPH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.80 - $4.94
Previous Close$0.85
Volume42.11K
Average Volume (3M)1.58M
Market Cap
$3.11M
Enterprise Value$3.27M
Total Cash (Recent Filing)$156.66K
Total Debt (Recent Filing)$314.26K
Price to Earnings (P/E)―
Beta0.34
Next Earnings
Sep 04, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.20
Shares Outstanding3,664,919
10 Day Avg. Volume87,798
30 Day Avg. Volume1,576,888
Standard Deviation0.28
R-Squared0.01
Alpha-0.12
Financial Highlights & Ratios
Price to Book (P/B)-2.49
Price to Sales (P/S)228.22
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue228.23
Enterprise Value/Gross Profit417.63
Enterprise Value/Ebitda-0.46
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Shuttle Pharmaceuticals Holdings, Inc. News
PremiumCompany Announcements
Shuttle Pharmaceuticals Starts Phase 2 Trial for Glioblastoma
PremiumCompany Announcements
Shuttle Pharma Raises $4.5M for Clinical Trials
PremiumMarket News
3 Penny Stocks to Watch Now, 10/31/24
PremiumCompany Announcements
Shuttle Pharmaceuticals Advances Phase 2 Glioblastoma Trial
Ownership Overview
37.22% Insiders
0.10% Mutual Funds
― Other Institutional Investors
62.68% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
SHPH FAQ
What was Shuttle Pharmaceuticals Holdings, Inc.’s price range in the past 12 months?
Shuttle Pharmaceuticals Holdings, Inc. lowest stock price was $0.80 and its highest was $4.94 in the past 12 months.
What is Shuttle Pharmaceuticals Holdings, Inc.’s market cap?
Currently, no data Available
When is Shuttle Pharmaceuticals Holdings, Inc.’s upcoming earnings report date?
Shuttle Pharmaceuticals Holdings, Inc.’s upcoming earnings report date is Sep 04, 2024 which is 109 days ago.
How were Shuttle Pharmaceuticals Holdings, Inc.’s earnings last quarter?
Shuttle Pharmaceuticals Holdings, Inc. released its earnings results on May 14, 2024. The company reported -$0.834 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.834.
Is Shuttle Pharmaceuticals Holdings, Inc. overvalued?
According to Wall Street analysts Shuttle Pharmaceuticals Holdings, Inc.’s price is currently Overvalued.
Does Shuttle Pharmaceuticals Holdings, Inc. pay dividends?
Shuttle Pharmaceuticals Holdings, Inc. does not currently pay dividends.
What is Shuttle Pharmaceuticals Holdings, Inc.’s EPS estimate?
Shuttle Pharmaceuticals Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shuttle Pharmaceuticals Holdings, Inc. have?
Shuttle Pharmaceuticals Holdings, Inc. has 3,664,919 shares outstanding.
What happened to Shuttle Pharmaceuticals Holdings, Inc.’s price movement after its last earnings report?
Shuttle Pharmaceuticals Holdings, Inc. reported an EPS of -$0.834 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.439%.
Which hedge fund is a major shareholder of Shuttle Pharmaceuticals Holdings, Inc.?
Currently, no hedge funds are holding shares in SHPH
---
Shuttle Pharmaceuticals Holdings, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-78.16%
12-Months-Change
Fundamentals
Return on Equity
-427.85%
Trailing 12-Months
Asset Growth
-90.87%
Trailing 12-Months
Company Description
Shuttle Pharmaceuticals Holdings, Inc.
Shuttle Pharmaceuticals Holdings Inc is a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments by leveraging insights into the pillars of cancer therapy: surgery, radiation therapy, chemotherapy, and immunotherapy.
---
Technical Analysis
---